 NBDA is a 501C3 non-profit. We will operationalize the assembly and, if necessary, the creation of the science to enable every single phase of biomarker development. A biomarker is a specific change in a normal or a disease process. It's actually a signal. They will allow us to measure changes in disease that are reproducible and will give us indications of how to treat a patient very, very specifically. So a biomarker is, as the name implies, a marker of biology. A biology in both health and disease. And the question of how we actually work out the signatures of biomarkers or if you like the fingerprint of what's gone wrong in disease at the molecular level, that is the hunt for biomarkers. Biomarkers are actually the way to transition from sick care to health care. The 20th century has been dedicated to taking care of very sick patients, wasting a lot of money actually on over-treatment or under-treatment, because we don't know the underlying cause and mechanisms of these diseases. Now we have the tools to the sequencing of the human genome and advanced technologies. We now have biomarkers. These measures of changes in disease that can lead us to develop personalized therapies for every person in the United States and actually around the world. There are some studies that are published in biomarkers that not only are worthless, but are actually detrimental, that actually lead to other researchers trying to validate them. It becomes very, very complex indeed. And so the question of how you create national standards for the types of tests that now need to be done in the genetic era is the real reason why this has been established. The National Biomarker Development Alliance has derived from a real unmet need in this country and around the world. We have no predictable end-to-end approach to develop biomarkers. A biomarker is not just discovered, it has to be developed. So development is modular. There are stages to biomarker development. Every stage involves decision making. There are no standards, no guidelines, no best practices for any of those stages. So as a consequence, all of those biomarkers, or most of them, are failing. So the mission of the National Biomarker Development Alliance is to actually create that evidence-based end-to-end process that will give us a predictable path to successful biomarker development. This is an extraordinarily difficult challenge, but one that we believe we can meet. We've assembled already hundreds of experts to work on these problems, to identify these barriers, and we welcome everyone and anyone to join the NBDA and come up with really unique solutions.